Testing a new shot for patchy hair loss (alopecia areata)
Part of Skin clinical trials.
This study tests a new medicine called ALD-102, given as a small shot in the scalp, to see if it helps hair grow back in people with alopecia areata. It is an early-stage trial looking at safety, how the body handles the drug, and whether it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old.
- You must have patchy hair loss (alopecia areata) on your scalp that has lasted more than 6 months but less than 5 years.
- You need to have a scalp area large enough to receive 20 to 40 tiny injections every 4 weeks.
- You must be willing to keep the same hairstyle and avoid dyeing or shaving your scalp within 2 weeks of study visits.
- You cannot be pregnant, breastfeeding, or planning pregnancy during the study.
- You cannot have very severe hair loss (affecting almost all of your scalp) or other scalp conditions that could interfere with the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HCW9302, that targets the immune system to help hair regrow in people with alopecia areata (including extensive forms like totalis or universalis). It may be an option for adults who have not responded well to other treatments.
This trial studies dupilumab (an injection medicine) to help grow hair in children and teens with alopecia areata, an autoimmune hair-loss condition. It aims to see whether the treatment improves hair regrowth compared with usual care over the study period.
This study tests if the medicine ritlecitinib can help regrow hair in people with alopecia areata, a condition that causes patchy hair loss. It's for young people and adults who have lost between 20% and 50% of their scalp hair for at least 6 months but no more than 10 years.
This study tests an experimental treatment using a substance made from your own hair follicles to see if it can help regrow hair in people with pattern baldness. It involves getting several small injections into your scalp over time.
This Phase 2 trial tests dupilumab (an injection medicine) to regrow hair in people with alopecia areata, a condition where the immune system attacks hair follicles. It may help by reducing the immune-related inflammation linked to hair loss.
This trial tests a new drug called FB102 for people with severe to very severe alopecia areata, a condition that causes at least half of scalp hair to be lost. It aims to see if the drug is safe and can help hair grow back.
Hear when a new Alopecia Areata (AA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.